Beow Yeap has collaborated closely with investigators in radiation oncology, radiation physics, medical oncology, molecular pathology, and thoracic surgery at the MGH Cancer Center and Dana-Farber/Harvard Cancer Center since joining MGH Biostatistics in 1999. She has developed extensive experience and expertise in design and analysis of clinical trials and correlative studies for adult and pediatric tumors, with primary focus on proton radiation therapy and molecularly targeted therapies.
Her contributions to translational research encompass preclinical models as well as human studies, including the identification and validation of biomarkers for prognosis and prediction of therapeutic benefit. She has played a leadership role in multi-disciplinary, multi-institutional research efforts as Director of the Biostatistics Core for the Program Project in proton therapy research and DF/HCC SPORE in Lung Cancer.
In between her degree studies for an A.M. in Statistics from the Harvard Graduate School of Arts & Sciences and an Sc.D. in Biostatistics from the Harvard T.H. Chan School of Public Health, she gained valuable experience in cancer clinical trials at the Dana-Farber Cancer Institute.
David Schoenfeld developed the first omnibus goodness of fit test for the proportional hazards regression model, a model that is used extensively in clinical trials which have survival or time to progression as an endpoint.
He also developed widely used graphical techniques for this model. He authored a popular web site for sample size considerations for clinical trials. He has also developed, along with Dianne Finkelstein, a method of combining endpoints in clinical trials which is favored by the Food and Drug Administration, and he has done research in Bayesian methods for evaluating historically controlled trials and small pediatric trials.
Dr. Schoenfeld was the principal investigator of the Clinical Coordinating Center for the Prevention and Early Treatment of Acute Lung Injury Clinical Network and its successor the Prevention and Early Treatment of Acute Lung Injury network, a national group doing clinical trials in Sepsis and Respiratory Failure. He is a leading statistician in Clinical Trials in Amyotrophic Lateral Sclerosis(ALS).
Currently he is available on a per diem basis for short term consultations on the design and analysis of clinical trials.
Brian Healy is an Associate Professor of Neurology at Harvard Medical School (HMS) and an Associate Professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. He is the primary biostatistician for the Partners MS Center at Brigham and Women’s Hospital, and he is a member of Massachusetts General Hospital (MGH) Biostatistics. Dr. Healy has been the instructor for many courses related to biostatistics at HMS and Harvard T.H. Chan School of Public Health. Dr. Healy’s research focuses on modeling the disease course in patients with multiple sclerosis.
He obtained his PhD in Biostatistics from the Harvard T.H. Chan School of Public Health in 2007.
Hang Lee joined MGH Biostatistics Center in 2001. He is Associate Director of Collaborative Research & Consulting at the Center and Associate Professor of Medicine at Harvard medical School. He also serves as Associate Director of the Harvard Catalyst (Center for Translational and Clinical Science) Biostatistics Program housed at MGH Biostatistics Center, and lead statistician for the MGH Division of Clinical Research (DCR) Biostatistics Unit. Dr. Lee has extensive collaborative research experience with clinical departments and research programs involving cooperative group coordinating center lead statistician role for national multi-center clinical trials and collaboration with study teams and individual investigators on designing clinical studies, and he co-authored a wide range of collaborative research articles.
Dr. Lee earned his PhD in Biometry from University of Southern California. Dr. Lee’s methodological interests are in the robust inference on clustered- and longitudinal outcomes. Before joining the Center, he was Research Fellow in Biostatistics at Harvard School of Public Health; Instructor at Harvard Department of Psychiatry and Harvard Institute of Psychiatric Epidemiology and Psychiatric Genetics at Massachusetts Mental Health Center; and Director of Biostatistics at UCLA Center for Vaccine Research and Assistant Professor at UCLA School of Medicine.
Eric Macklin is an Instructor in Investigation at Massachusetts General Hospital and an Instructor in Medicine at Harvard Medical School. His research interests focus on neurodegenerative and neurodevelopmental diseases with an emphasis on clinical trial design.
He is an Executive Committee member of the Parkinson Study Group and an academic advisor for the Critical Path for Parkinson’s Consortium. He was an organizing member and the lead biostatistician for the Airlie House Clinical Trials Guidelines for ALS research. He is a lead biostatistician for the Healey ALS Center Platform trial, for the phase 3 SURE-PD3 trial in Parkinson disease, and for the Autism Treatment Network. In addition to his work in neurology, he has a long and ongoing interest in evaluation of complementary and alternative medicine, serving as PI or statistician for trials of acupuncture, Tai Chi, and mind-body practices.
Dr. Macklin earned a PhD from Duke University and also holds an MS from Stanford University and an MSc from the Harvard T.H. Chan School of Public Health.
Robert Parker is an Associate Investigator in MGH Biostatistics and an Associate Professor of Medicine at Harvard Medical School.
He is an Associate Director of the Biostatistics and Bioinformatics Core of the Harvard Center for AIDS Research, and Director of the Data Coordinating Center for the PRIME-AIR study. In addition, he works on multiple other R01 studies in HIV (both domestic and international) and has recently started working on projects with the Center for Health Outcomes and Interdisciplinary Research (CHOIR) at MGH.
His research interests are in non-standard study design, non-standard data analysis, and the art of statistical consulting. He is a co-author of the textbook “Planning Clinical Research” published by Cambridge University Press.
Dr. Parker earned an ScD in Biostatistics from the Harvard School of Public Health and an MSc in Medical Statistics from the London School of Hygiene and Tropical Medicine.
Dustin J. Rabideau is Associate Director, Biostatistics and Strategic Initiatives for MGH Biostatistics and an Assistant Professor of Medicine at Harvard Medical School. Dr. Rabideau’s biostatistical research focuses on robust analysis methods for cluster randomized trials and innovative methods to account for participant dropout in clinical trials. Dr. Rabideau also has extensive collaborative research experience providing statistical leadership and expertise for various investigators across MGH. His current research partnerships include the Dauten Family Center for Bipolar Treatment Innovation and the Cancer Outcomes Research and Education Program.
Dr. Rabideau earned a PhD in Biostatistics from the Harvard T.H. Chan School of Public Health. He also holds a MS and MA in Biostatistics from Harvard and a BA in Mathematics and French from SUNY Geneseo.
Marie-Abèle Bind is an Assistant Professor of Medicine at Harvard Medical School and Assistant Investigator at MGH Biostatistics. Her research interests focus on defining the causal questions being asked by describing real or hypothetical multi-factorial interventions, developing causal inference methods for quantifying the effects of randomized and non-randomized exposures on health outcomes and understanding the mechanisms explaining these health effects. Her current research has been funded by the NIH Early Independence Award program.
Dr. Bind completed her joint PhD in Biostatistics and Environmental Health at the Harvard School of Public Health, working with Professors Brent Coull and Joel Schwartz. She then became a Ziff postdoctoral Fellow at the Harvard University Center for the Environment. In 2016, she was awarded an Early Independence Award (NIH High-Risk High-Reward research grant) and became Research Associate in the Department of Statistics. From 2017 to 2021, she became a John Harvard Distinguished Science Fellow.
Dianne Finkelstein is a Professor of Medicine at Harvard Medical School, Professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and a biostatistician at Massachusetts General Hospital.
After ten years of leadership, she recently stepped down as Director of MGH Biostatistics. Her research interests focus on cancer clinical research and statistical methods for survival analysis and longitudinal outcomes in clinical trials and epidemiology studies.
Dr. Finkelstein earned a Ph.D. in Biostatistics from the University of Michigan.
